Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
Helmut Butzkueven, Stephanie Licata, Douglas Jeffery, Douglas L. Arnold, Massimo Filippi, Jeroen J.G. Geurts, Sourav Santra, Nolan Campbell, Pei‐Ran Ho (2020). Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. , 10(10), DOI: https://doi.org/10.1136/bmjopen-2020-038861.
